Hong Kong Stock Movement | ABBISKO-B (02256) Surges Over 7% Amid Presentation of Pimicotinib Phase III Study Data at 2025 ESMO Conference

Stock News

10/27

ABBISKO-B (02256) experienced a rise of over 7% during trading, currently up 6.06% at HKD 15.03, with a trading volume of HKD 9.1686 million. In recent news, ABBISKO-B announced that its subsidiary, Shanghai ABBISKO Biopharmaceutical Technology Co., Ltd. (ABBISKO Pharmaceuticals), has presented long-term efficacy and safety data from the global Phase III MANEUVER study of pimicotinib (ABSK021) for patients with tenosynovial giant cell tumor (TGCT) in a verbal report at the 2025 European Society for Medical Oncology (ESMO) conference. Pimicotinib has been prioritized for review by the National Medical Products Administration (NMPA) of China for adult patients with TGCT requiring systemic treatment and has also received Breakthrough Therapy Designation (BTD) from the NMPA. Additionally, pimicotinib holds a BTD from the U.S. Food and Drug Administration (FDA) and has been granted Priority Medicines (PRIME) designation by the European Medicines Agency (EMA).

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1100490684"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1100490684\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1100490684?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-27 10:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100490684","market":"hk","top_or_hot":-1,"title":"Hong Kong Stock Movement | ABBISKO-B (02256) Surges Over 7% Amid Presentation of Pimicotinib Phase III Study Data at 2025 ESMO Conference","media":"Stock News","content":"<p>ABBISKO-B (02256) experienced a rise of over 7% during trading, currently up 6.06% at HKD 15.03, with a trading volume of HKD 9.1686 million. In recent news, ABBISKO-B announced that its subsidiary, Shanghai ABBISKO Biopharmaceutical Technology Co., Ltd. (ABBISKO Pharmaceuticals), has presented long-term efficacy and safety data from the global Phase III MANEUVER study of pimicotinib (ABSK021) for patients with tenosynovial giant cell tumor (TGCT) in a verbal report at the 2025 European Society for Medical Oncology (ESMO) conference. Pimicotinib has been prioritized for review by the National Medical Products Administration (NMPA) of China for adult patients with TGCT requiring systemic treatment and has also received Breakthrough Therapy Designation (BTD) from the NMPA. Additionally, pimicotinib holds a BTD from the U.S. Food and Drug Administration (FDA) and has been granted Priority Medicines (PRIME) designation by the European Medicines Agency (EMA).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Movement | ABBISKO-B (02256) Surges Over 7% Amid Presentation of Pimicotinib Phase III Study Data at 2025 ESMO Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Movement | ABBISKO-B (02256) Surges Over 7% Amid Presentation of Pimicotinib Phase III Study Data at 2025 ESMO Conference\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-10-27 10:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>ABBISKO-B (02256) experienced a rise of over 7% during trading, currently up 6.06% at HKD 15.03, with a trading volume of HKD 9.1686 million. In recent news, ABBISKO-B announced that its subsidiary, Shanghai ABBISKO Biopharmaceutical Technology Co., Ltd. (ABBISKO Pharmaceuticals), has presented long-term efficacy and safety data from the global Phase III MANEUVER study of pimicotinib (ABSK021) for patients with tenosynovial giant cell tumor (TGCT) in a verbal report at the 2025 European Society for Medical Oncology (ESMO) conference. Pimicotinib has been prioritized for review by the National Medical Products Administration (NMPA) of China for adult patients with TGCT requiring systemic treatment and has also received Breakthrough Therapy Designation (BTD) from the NMPA. Additionally, pimicotinib holds a BTD from the U.S. Food and Drug Administration (FDA) and has been granted Priority Medicines (PRIME) designation by the European Medicines Agency (EMA).</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"III","symbol_name":"信息服務","start_time":0,"source_url":"","article_id":"1100490684","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100490684","pubTimestamp":1761530770,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ABBISKO-B (02256) experienced a rise of over 7% during trading, currently up 6.06% at HKD 15.03, with a trading volume of HKD 9.1686 million. In recent news, ABBISKO-B announced that its subsidiary,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"III":"信息服务","02256":"和誉-B","BK1161":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4134":"信息科技咨询与其它服务"},"translate_title":"港股动向|2025年ESMO会议公布皮米替尼III期研究数据，和必拓-B(02256)大涨超7%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"III":1,"02256":1},"content_text":"ABBISKO-B (02256) experienced a rise of over 7% during trading, currently up 6.06% at HKD 15.03, with a trading volume of HKD 9.1686 million. In recent news, ABBISKO-B announced that its subsidiary, Shanghai ABBISKO Biopharmaceutical Technology Co., Ltd. (ABBISKO Pharmaceuticals), has presented long-term efficacy and safety data from the global Phase III MANEUVER study of pimicotinib (ABSK021) for patients with tenosynovial giant cell tumor (TGCT) in a verbal report at the 2025 European Society for Medical Oncology (ESMO) conference. Pimicotinib has been prioritized for review by the National Medical Products Administration (NMPA) of China for adult patients with TGCT requiring systemic treatment and has also received Breakthrough Therapy Designation (BTD) from the NMPA. Additionally, pimicotinib holds a BTD from the U.S. Food and Drug Administration (FDA) and has been granted Priority Medicines (PRIME) designation by the European Medicines Agency (EMA).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}